FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564776172> ?p ?o ?g. }

• W2564776172 endingPage "3002" @default.
• W2564776172 startingPage "3002" @default.
• W2564776172 abstract "3002 Background: FAK is a non-receptor tyrosine kinase that transduces signaling from integrins and growth factor receptors to modulate cell invasion, migration, metastasis and survival. PF-04554878 is a potent ATP-competitive inhibitor of FAK that also inhibits the related protein proline-rich tyrosine kinase (Pyk2). Methods: This is an ongoing phase 1 dose escalation study of PF-04554878 given as continuous oral dosing in 21-day cycles in patients (pts) with solid tumors. Endpoints include safety, pharmacokinetics (PK), and response by RECIST. Results: 36 patients (data cut-off 09 Dec 2010) received doses ranging from 12.5 mg to 750 mg BID on a fasting schedule. Demographics: M:F 16:20, and mean age: 56 yrs (range 31-84). Primary tumor types: colorectal (CRC) 15, pancreatic 4, ovarian 3, bile duct 3, breast 2, other 9. 72% of pts had ≥3 prior systemic treatments. Adverse events (AEs) possibly related to PF-04554878 in >10% pts: nausea (33%), vomiting (31%), unconjugated hyperbilirubinemia (28%), fatigue (25%), headache (19%), diarrhea (19%), and decreased appetite (17%). All AEs (including unconjugated hyperbilirubinemia) were typically CTCAE grades 1-2, easily managed and reversible even with continued dosing. There have been three dose limiting toxicities (DLTs): a grade 3 headache (at 200 mg BID), and two grade 3 unconjugated hyperbilirubinemias (at 300 mg BID and 425 mg BID). All DLTs were reversed on stopping drug. PK analysis supports the BID dosing regimen and shows that doses above 100 mg BID lead to exposures above the minimal efficacious concentration predicted preclinically. Increasing the dose beyond 425 mg BID did not increase drug exposure. Stable disease (SD) was observed at the end of 2 cycles in 12 (33%) pts once the dose reached ≥100 mg BID. Two of these pts (ovarian, CRC) had SD observed at the end of 6 cycles and a further two pts (bile duct, lung mucoepidermoid) had SD observed for ≥9 cycles. The recommended Phase 2 dose, on a fasting schedule, is 425 mg BID. Conclusions: Clinical safety, tolerability, PK, and the sustained disease control seen in some pts, all support further development." @default.
• W2564776172 created "2017-01-06" @default.
• W2564776172 creator A5000204204 @default.
• W2564776172 creator A5018089100 @default.
• W2564776172 creator A5028472820 @default.
• W2564776172 creator A5036379166 @default.
• W2564776172 creator A5042460988 @default.
• W2564776172 creator A5045232946 @default.
• W2564776172 creator A5054545886 @default.
• W2564776172 creator A5061036796 @default.
• W2564776172 creator A5066427694 @default.
• W2564776172 creator A5067414935 @default.
• W2564776172 creator A5067489081 @default.
• W2564776172 creator A5072202311 @default.
• W2564776172 creator A5074524339 @default.
• W2564776172 creator A5076615101 @default.
• W2564776172 date "2011-05-20" @default.
• W2564776172 modified "2023-09-27" @default.
• W2564776172 title "Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors." @default.
• W2564776172 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.3002" @default.
• W2564776172 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28022183" @default.
• W2564776172 hasPublicationYear "2011" @default.
• W2564776172 type Work @default.
• W2564776172 sameAs 2564776172 @default.
• W2564776172 citedByCount "9" @default.
• W2564776172 countsByYear W25647761722014 @default.
• W2564776172 countsByYear W25647761722015 @default.
• W2564776172 countsByYear W25647761722017 @default.
• W2564776172 countsByYear W25647761722018 @default.
• W2564776172 countsByYear W25647761722021 @default.
• W2564776172 countsByYear W25647761722022 @default.
• W2564776172 crossrefType "journal-article" @default.
• W2564776172 hasAuthorship W2564776172A5000204204 @default.
• W2564776172 hasAuthorship W2564776172A5018089100 @default.
• W2564776172 hasAuthorship W2564776172A5028472820 @default.
• W2564776172 hasAuthorship W2564776172A5036379166 @default.
• W2564776172 hasAuthorship W2564776172A5042460988 @default.
• W2564776172 hasAuthorship W2564776172A5045232946 @default.
• W2564776172 hasAuthorship W2564776172A5054545886 @default.
• W2564776172 hasAuthorship W2564776172A5061036796 @default.
• W2564776172 hasAuthorship W2564776172A5066427694 @default.
• W2564776172 hasAuthorship W2564776172A5067414935 @default.
• W2564776172 hasAuthorship W2564776172A5067489081 @default.
• W2564776172 hasAuthorship W2564776172A5072202311 @default.
• W2564776172 hasAuthorship W2564776172A5074524339 @default.
• W2564776172 hasAuthorship W2564776172A5076615101 @default.
• W2564776172 hasConcept C126322002 @default.
• W2564776172 hasConcept C143998085 @default.
• W2564776172 hasConcept C197934379 @default.
• W2564776172 hasConcept C2777288759 @default.
• W2564776172 hasConcept C2780580376 @default.
• W2564776172 hasConcept C2780852908 @default.
• W2564776172 hasConcept C71924100 @default.
• W2564776172 hasConcept C90924648 @default.
• W2564776172 hasConcept C98274493 @default.
• W2564776172 hasConceptScore W2564776172C126322002 @default.
• W2564776172 hasConceptScore W2564776172C143998085 @default.
• W2564776172 hasConceptScore W2564776172C197934379 @default.
• W2564776172 hasConceptScore W2564776172C2777288759 @default.
• W2564776172 hasConceptScore W2564776172C2780580376 @default.
• W2564776172 hasConceptScore W2564776172C2780852908 @default.
• W2564776172 hasConceptScore W2564776172C71924100 @default.
• W2564776172 hasConceptScore W2564776172C90924648 @default.
• W2564776172 hasConceptScore W2564776172C98274493 @default.
• W2564776172 hasIssue "15_suppl" @default.
• W2564776172 hasLocation W25647761721 @default.
• W2564776172 hasOpenAccess W2564776172 @default.
• W2564776172 hasPrimaryLocation W25647761721 @default.
• W2564776172 hasRelatedWork W1980872763 @default.
• W2564776172 hasRelatedWork W1983907859 @default.
• W2564776172 hasRelatedWork W2034199439 @default.
• W2564776172 hasRelatedWork W2041128529 @default.
• W2564776172 hasRelatedWork W2164530441 @default.
• W2564776172 hasRelatedWork W2358248846 @default.
• W2564776172 hasRelatedWork W2376132146 @default.
• W2564776172 hasRelatedWork W2384102814 @default.
• W2564776172 hasRelatedWork W243857094 @default.
• W2564776172 hasRelatedWork W3134060499 @default.
• W2564776172 hasVolume "29" @default.
• W2564776172 isParatext "false" @default.
• W2564776172 isRetracted "false" @default.
• W2564776172 magId "2564776172" @default.
• W2564776172 workType "article" @default.